GPC1 and neoplasm: GPCs have been suggested to act as biomarkers for tumor progression, such as GPC3 for hepatocellular carcinoma13,14, GPC1 for pancreatic ductal adenocarcinoma15, and GPC5 and GPC1 for prostate cancer16,17.